Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Niet-farmacologische behandeling versus farmacologische behandeling voor niet-acute lumbale hernia

16 september 2026 bijgewerkt door: Jaseng Medical Foundation

Vergelijkende effectiviteit van niet-farmacologische behandeling en farmacologische behandeling voor niet-acute lumbale hernia: een multi-gecentreerde, pragmatische, gerandomiseerde, gecontroleerde, parallel gegroepeerde studie

This is a randomized controlled study comparing non-pharmacological treatment to proactive pharmacological treatment for patient with non-acute lumbar disc herniation with moderate or higher levels of pain. The study involves 200 adult patients aged 19-69, with 50 patients from each participating hospital. Patients will be randomly assigned to either the non-pharmacological treatment group or the pharmacological treatment group 1:1 ratio. Specific interventions will be determined by doctors and Korean medicine doctors without predefined treatment strategies. The non-pharmacological treatment include acupuncture, electroacupuncture, spinal manual therapy and motion style acupuncture. The pharmacological treatment include medication prescription, injection, and nerve block. Treatment period is 8 weeks, and f/u for 3 years.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This is a pragmatic, multi-centered, randomized controlled, parallel-grouped study aiming to compare the effectiveness of a non-pharmacological treatment strategy and a active pharmacological treatment strategy in managing non-acute lumbar disc herniation with moderate or higher levels of pain persisting for more than one month in adult men and women aged 19 to 69 years.

The study will include 200 patients with lumbar disc herniation, with 50 patients from each of the participating hospitals (Jaseng Hospital of Korean Medicine, Daejeon Jaseng Hospital of Korean Medicine, Bucheon Jaseng Hospital of Korean Medicine, Haeundae Jaseng Hospital of Korean Medicine, competitively recruited). The patients will be assigned in a 1:1 ratio to receive either non-pharmacological treatment (100 patients) or active pharmacological treatment (100 patients) in a pragmatic randomized controlled design. The specific interventions for each group will be determined based on clinical judgment by the doctors and Korean medicine doctors involved in the study, without predefining the treatment strategies. The treatment methods, including acupuncture, electroacupuncture, spinal maunal therapy and motion style acupuncture, will be recorded in the case report form for comparative analysis.

For the non-pharmacological treatment group, patients will be recommended to receive non-pharmacological treatment based on TKM. The frequency and specifics of the treatment will be determined by the clinical judgment of the doctors and Korean medicine doctors based on the patient's symptoms, MRI images, and clinical improvement. The treatment will be conducted twice a week for a total of eight weeks, but the frequency may be adjusted according to the patient's condition. Concurrent therapies and adjuvant therapies can be freely chosen by the patients, and the details will be recorded in the case report form.

For the pharmacological treatment group, patients will be educated about proactive pharmacological treatment and recommended to receive pharmacological treatment. The specific pharmacological interventions, such as prescription medication, injection therapy, and nerve block, will be determined by the doctors based on the patient's symptoms, imaging results, and clinical judgment. The details of the prescribed medication, dosage, administration route, and duration will be recorded in the case report form. Similar to the non-pharmacological treatment group, concurrent therapies and adjuvant therapies can be chosen by the patients, and the details will be recorded.

The treatment frequency for the pharmacological treatment group will also be twice a week for a total of eight weeks, with adjustments based on the patient's condition. The effectiveness of the treatment strategies will be assessed through weekly evaluations of the patients' symptoms and treatment progress.

It should be noted that patients are not obligated to strictly follow the assigned treatment strategy, as this is a study recommending a particular treatment strategy rather than enforcing it as a protocol violation.

Studietype

Ingrijpend

Inschrijving (Geschat)

200

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Zuid -Korea
      • Busan, Zuid -Korea
        • Werving
        • Haeundae Jaseng Hospital of Korean Medicine
        • Contact:
          • Hyun Woo Cho, PhD
        • Contact:
      • Daejeon, Zuid -Korea
        • Werving
        • Daejeon Jaseng Hospital of Korean Medicine
        • Contact:
    • Gangnam-Gu
      • Seoul, Gangnam-Gu, Zuid -Korea, 135-896
        • Werving
        • Jaseng Hospital of Korean Medicine
        • Contact:
    • Gyeonggi-do
      • Bucheon-si, Gyeonggi-do, Zuid -Korea, 14598
        • Werving
        • Bucheon Jaseng Hospital of Korean Medicine
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

19 jaar tot 69 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • aged 19 to 69 years.
  • lower back pain that has persisted for at least 1 month.
  • a Numeric Rating Scale (NRS) score of 5 or higher for either lower back pain or radiating leg pain over the past three consecutive days.
  • confirmed lumbar disc herniation on MRI that can explain the lower back pain.
  • who have provided written informed consent and agreed to participate in the clinical study.

Exclusion Criteria:

  • diagnosed with specific severe diseases that could be the cause of lower back pain or leg pain (e.g., spinal metastasis, acute fractures, and spinal dislocation).
  • showing progressive neurological deficits or severe neurological symptoms.
  • with pain originating from soft tissue disorders other than the spine (e.g., tumors, fibromyalgia, rheumatoid arthritis, gout).
  • with other chronic conditions (e.g., stroke and myocardial infarction, renal disease, diabetic neuropathy, dementia, epilepsy) that may interfere with the treatment effect or result interpretation.
  • taking steroids, immunosuppressive drugs, psychiatric medications, or other medications that may impact the study results.
  • acupuncture or nerve block treatment is inappropriate or unsafe, such as those with a history of bleeding disorders, receiving anticoagulant therapy, or diagnosed with uncontrolled diabetes.
  • taken non-steroidal anti-inflammatory drugs (NSAIDs) or other pain-affecting drugs or received acupuncture treatment within the past 5 days.
  • Pregnant women, those planning pregnancy, or breastfeeding women.
  • within 3 months after lumbar surgery.
  • who have not completed participation in another clinical study within the past month or have plans to participate in another clinical study within 6 months from the selection date or during the study participation and follow-up period.

Inability to provide written informed consent.

- Other cases where the researchers determine that participation in the clinical study would be difficult.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Non-pharmacological treatment strategy

Interventions: Non-pharmacological treatment include acupuncture, electroacupuncture, spinal manual therapy, and motion style acupuncture treatment.

Frequency: Not specified (Twice a week recommended) Duration: Eight weeks.
Procedure: non-pharmacological treatment strategy

Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
Actieve vergelijker: Pharmacological treatment strategy

Interventions: Active pharmacological treatment involving prescription medication, injection therapy, or other pharmacological interventions.

Frequency: Not specified (Twice a week recommended) Duration: Eight weeks.
Procedure: pharmacological treatment strategy

Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.

This group is treated using the above treatment strategies, and no drug is specified.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Oswestry Disability Index (ODI)
Tijdsspanne: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The Oswestry Disability Index (ODI) is a questionnaire used to assess the functional status and degree of disability caused by lower back pain. It consists of 10 items that evaluate various aspects of daily activities and mobility. Each item is rated on a 6-point scale, with higher scores indicating a greater level of disability.

From 0 to 100. Higher scores mean a worse outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
Numeric Rating Scale for Pain of Dominant Change (NRS for DC)
Tijdsspanne: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

The study will evaluate the intensity of lower back pain and radiating leg pain using the Numeric Rating Scale (NRS). Patients will rate their pain levels on a scale from 0 to 10, where 0 represents no pain and 10 represents the most severe imaginable pain. The NRS for Dominant Change (NRS-DC) will be calculated as the higher value between the change in NRS scores from baseline for lower back pain and radiating leg pain. The NRS-DC will serve as a key evaluation indicator for pain intensity.
Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Recurrence
Tijdsspanne: Week 13, 26, 39, 52, Month 18, 24, 36

This study will confirm the recurrence of symptoms in patients through a yes or no response.
Week 13, 26, 39, 52, Month 18, 24, 36
Numeric Rating Scale (NRS) for Low Back Pain
Tijdsspanne: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10. The participants are asked to report their low back pain and discomfort using NRS, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable.
Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36
Patient Global Impression of Change (PGIC)
Tijdsspanne: Week 9, 13, 26, 39, 52, Month 18, 24, 36

Participants rate the improvement after treatment on a 7-point Likert scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.)
Week 9, 13, 26, 39, 52, Month 18, 24, 36
Fear-Avoidance Beliefs Questionnaire (FABQ)
Tijdsspanne: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The fear-avoidance belief questionnaire (FABQ) is a questionnaire based on the fear-avoidance model of exaggerated pain perception. The FABQ measures patient's fear of pain and consequent avoidance of physical activity (PA) because of their fear.

Minimum 0 to maximum 66 scores. Higher score means a worse outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
Short Form-12 Health Survey version 2 (SF-12 v2)
Tijdsspanne: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The SF-12 consists of 12 questions across 8 domains, and higher scores indicate better health-related quality of life.

Ranging from 0 to 100, higher score means a better outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
EuroQol-5 Dimension (EQ-5D-5L)
Tijdsspanne: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The EQ-5D-5L consists of 5 questions (mobility, self-care, usual activities, pain, anxiety/depression) that ask about the current state of health, and answers each question with 5 likert. (1=I have no problems about, 2=I have slight problems about, 3=I have moderate problems about, 4=I have severe problems about, 5=I am unable to about) Ranging from 0 to 1, higher score means a better outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
Credibility and Expectancy
Tijdsspanne: Baseline

The study will measure the level of trust and expectation regarding the effectiveness of the treatment through two questions:

On a scale from 0 to 10, how much do you believe that traditional herbal medicine treatment will alleviate your symptoms? On a scale from 0 to 10, how much do you believe that drug therapy will alleviate your symptoms? 0 indicates no belief or expectation, and 10 indicates full belief and high expectation.
Baseline
Intention to Treat
Tijdsspanne: Week 9

Evaluate participants' intentions if they are willing to receive non-pharmacological treatment strategies or pharmacological treatment strategies in the future on a scale from 0 to 9. 0 indicates no intention, and 10 indicates full belief and high intention.
Week 9
Work Productivity and Activity Impairment-Specific Health Problem
Tijdsspanne: Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Productivity loss will be assesed by WPAI-SHP. Through the WPAI questionnaire, the overall work productivity, which is a concept combining absenteesim and presenteeism, as well as employment will be investigated and used as outcomes.
Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36
Classification of Disc Degeneration
Tijdsspanne: Week 1, 26, 52, Month 24, 36

Classify the degree of disc degeneration based on the Pfirrmann grading system.
Week 1, 26, 52, Month 24, 36
Stages to a Disc Herniation
Tijdsspanne: Week 1, 26, 52, Month 24, 36

Classify the stage of disc herniation as bulging, protrusion, extrusion, or sequestration/migration.
Week 1, 26, 52, Month 24, 36
Herniated Disc Areas
Tijdsspanne: Week 1, 26, 52, Month 24, 36

Measure the area of the most significant transverse plane slice of the herniated disc on MRI.
Week 1, 26, 52, Month 24, 36
Cost Data Survey
Tijdsspanne: Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Measure various cost items related to the treatment, including medical costs, non-medical costs, time costs, and productivity loss costs.
Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Jaseng Medical Foundation

Onderzoekers

  • Studie directeur: In-Hyuk Ha, Dr, Jaseng Medical Foundation

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

9 augustus 2023

Primaire voltooiing (Geschat)

31 december 2030

Studie voltooiing (Geschat)

31 december 2030

Studieregistratiedata

Eerst ingediend

20 juli 2023

Eerst ingediend dat voldeed aan de QC-criteria

29 augustus 2023

Eerst geplaatst (Werkelijk)

6 september 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

21 september 2026

Laatste update ingediend die voldeed aan QC-criteria

16 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • JS-CT-2023-02

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren